Imugene CMO and CEO talk trial momentum and immuno-oncology progress

0 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
Newly minted Imugene Ltd chief medical officer (CFO) Dr John Byon talked with Proactive about the company’s recent progress in its immuno-oncology programs. Byon outlined his background in haematologic oncology and biopharma development, having worked at Fate Therapeutics, Lyell Immunopharma, Juno Therapeutics and Genentech before joining Imugene.

He said Azer-cel is currently being evaluated in patients who have failed prior autologous CAR-T therapies, addressing a significant unmet medical need. “We are starting to see not just responses but durable responses,” Byon noted, adding that durability is critical for improving patient quality of life.

CEO Leslie Chong highlighted the significance of Byon’s promotion to CMO, crediting his leadership with progress across multiple programs, including CF33 and out-licensing opportunities in immunotherapy. She said his work has driven “profound responses as well as durability” in the company's programs development.

The pair also discussed the activation of the first site in a Phase 2 trial of its Neo-POLEM trial, expanding the clinical investigation of its PD1-Vaxx immunotherapy for a difficult-to-treat form of colorectal cancer.

To hear more insights and updates from Imugene, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and turn on notifications for future content.

#Imugene #AzerCel #CancerTreatment #Immunotherapy #BiotechNews #CAR_T #OncologyResearch #PD1Vaxx #Biopharma #ProactiveInvestors
Category
Oncology
Be the first to comment

Up Next